The startup has developed a medical device that utilizes alternating magnetic fields generated by external coils to eliminate biofilm from the surfaces of infected metallic implants. This non-invasive treatment addresses complications associated with surgeries such as knee and hip replacements, as well as trauma-related implants like plates and rods.
Funding
$13.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MIFounders
Product
Problem
Infections following metallic implant surgeries, such as knee and hip replacements, pose a significant challenge due to biofilm formation on the implant surface. Current treatments often require risky and expensive revision surgeries to remove the infected implant.
Solution
Solenic Medical is developing a non-invasive solution for treating infections associated with metallic implants. The SOLA2 system utilizes patented alternating magnetic field (AMF) technology to generate a controlled thermal dose on the metallic implant, effectively eradicating biofilm and killing bacteria within a millimeter of the implant surface. This approach aims to reduce the need for revision surgeries, improve patient outcomes, and transform the standard of care for implant-related infections. The AMF technology works synergistically with antibiotics, making it easier for the immune system to clear the infection.
Target Audience
The primary target audience includes orthopedic surgeons and hospitals dealing with patients who have confirmed or suspected periprosthetic joint infections (PJI) following metallic implant surgeries.
Features
- Non-invasive treatment using alternating magnetic fields (AMF)
- Targeted heating of metallic implants to eradicate biofilm
- Controlled thermal dose to kill bacteria without damaging surrounding tissue
- Synergistic effect with antibiotics to enhance infection clearance
- SOLA2 AMF Knee System designed for use in an operating room setting
- First-in-Human IDE approved by FDA and in progress